Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. on July 24, 2009. The filing discloses the completion of a previously announced equity offering under an existing shelf registration statement (File No. 333-160251) declared effective by the SEC on July 17, 2009.
Key Financial Metrics
- Gross Proceeds: Approximately $9.5 million.
- Shares Sold: 475,000 shares of common stock.
- Price Per Share: $20.00.
- Transaction Type: Direct sale to institutional investors with no placement agent or underwriter.
- Net Proceeds: The filing states gross proceeds before deducting expenses; net proceeds are not specified.
Material Changes
The primary material event is the successful execution of the equity offering, resulting in an increase in the company's cash position by approximately $9.5 million (gross). This transaction represents a significant capital raise for the period.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure of the transaction completion. The document incorporates a press release (Exhibit 99.1) by reference for further details.
Investor Verification Checklist
- Verify the exact amount of expenses deducted from the $9.5 million gross proceeds to determine net cash inflow.
- Review the full text of the press release (Exhibit 99.1) for details on the intended use of proceeds.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Check subsequent filings for any changes in the company's liquidity position or operational plans following this capital raise.